Typical cycle: 812 weeks on, followed by 48 weeks off
[1] The more advanced regulatory activity belongs to the combination product CagriSema (cagrilintide plus semaglutide), which reached Phase 3 and for which a New Drug Application was reported to have been filed with the FDA in late 2025
In 2015, the FDA addressed the concerns with a Safety Communication stating that it is safe and that the studies showing that it wasnt safe were all flawed.[ref] Lets take a look at some of the studies and then dig into the mechanism of action
Since, EAATs play an essential role in regulating glutamatergic synapses, there are many neurological disorders that are related to the impaired activity of glutamate transport
Zhang Y, Yang X, Wang S, Song S (2019) Ginsenoside Rg3 prevents cognitive impairment by improving mitochondrial dysfunction in the rat model of Alzheimers disease